New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 4, 2014
07:59 EDTGEVASynageva should be bought at current levels, says RW Baird
Baird said their investment thesis for Synageva remains unchanged following its successful display at the WORLD symposium last month. The firm recommends purchase at current levels as the company heads into an important value-creating period which includes potential pivotal data for a lead compound and the beginning of clinical trials for SBC-103. Shares are Outperform rated with a $107 price target.
News For GEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for GEVA

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use